Expression of EXO1 was higher in BRCA patients with pathologic stage II/III, infiltrating ductal carcinoma, age ≤60 years, PR-negative, ER-negative, HER2-positive, basal-like of PAM50 classification, and non-White race. Here, ERBB2 is linked to invasive ductal breast carcinoma.